Abstract
Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently affected than women. GBS is considered to be an autoimmune disease triggered by a preceding bacterial or viral infection. Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae are commonly identified antecedent pathogens.
In the acute motor axonal neuropathy (AMAN) form of GBS, the infecting organisms probably share homologous epitopes to a component of the peripheral nerves (molecular mimicry) and, therefore, the immune responses cross-react with the nerves causing axonal degeneration; the target molecules in AMAN are likely to be gangliosides GM1, GM1b, GD1a and Ga1NAc-GD1a expressed on the motor axolemma. In the acute inflammatory demyelinating polyneuropathy (AIDP) form, immune system reactions against target epitopes in Schwann cells or myelin result in demyelination; however, the exact target molecules in the case of AIDP have not yet been identified. AIDP is by far the most common form of GBS in Europe and North America, whereas AMAN occurs more frequently in east Asia (China and Japan).
The prognosis of GBS is generally favourable, but it is a serious disease with a mortality of approximately 10% and approximately 20% of patients are left with severe disability. Treatment of GBS is subdivided into: (i) the management of severely paralysed patients with intensive care and ventilatory support; and (ii) specific immunomodulating treatments that shorten the progressive course of GBS, presumably by limiting nerve damage. High-dose intravenous immunoglobulin (IVIg) therapy and plasma exchange aid more rapid resolution of the disease. The predominant mechanisms by which IVIg therapy exerts its action appear to be a combined effect of complement inactivation, neutralisation of idiotypic antibodies, cytokine inhibition and saturation of Fc receptors on macrophages. Corticosteroids alone do not alter the outcome of GBS.
Similar content being viewed by others
References
Olive JM, Castillo C, Castro RG, et al. Epidemiologic study of Guillain-Barré syndrome in children <15 years of age in Latin America. J Infect Dis 1997; 175 Suppl. 1: S160–4
Hahn AF. Guillain-Barré syndrome. Lancet 1998; 352(9128): 635–41
Asbury AK, Arnarson BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine 1969; 48(3): 173–215
Ropper AH. Diseases of spinal cord, peripheral nerve, and muscle. In: Victor M, Ropper AH, editors. Principle of neurology. New York: McGraw-Hill, 2001: 1380–7
Rees JH, Thompson RD, Smeeton NC, et al. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64(1): 74–7
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997; 176 Suppl. 2: S92–8
Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56(8): 1104–6
Nachamkin I. Epidemiology of Campylobacter jejuni infections in the United States and other industrial nations. In: Tauxe RV, Nachamkin I, Blaser MJ, et al., editors. Campyiobacter jejuni: current status and future trends. Washington, DC: American Society for Microbiology, 1992: 9–19
Sheikh KA, Nachamkin I, Ho TW, et al. Campyiobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology 1998; 51(2): 371–8
Feasby TE, Hughes RAC. Campyiobacter jejuni, anti-ganglioside antibodies, and Guillain-Barré syndrome. Neurology 1998; 51(2): 340–2
Yuki N, Sato S, Fujimoto S, et al. Serotype of Campyiobacter jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve 1992; 15(8): 968–9
Ma JJ, Nishimura M, Mine H, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome. Neurology 1998; 51(2): 379–84
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome: Plasma Exchange/Sandglobulin Guillain Barré Syndrome Trial Group. Ann Neurol 1998; 44(5): 780–8
Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109 (Pt 6): 1115–26
Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases. Brain 1995; 118 (Pt 3): 577–95
Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of Guillain-Barré syndrome. J Neurocytol 1996; 25(1): 33–51
Prineas JW. Acute idiopathic polyneuritis: an electron microscope study. Lab Invest 1972; 26(2): 133–47
Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol 1981; 9 Suppl.: 6–19
Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campyiobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 (Pt 3): 597–605
McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991; 338(8767): 593–7
McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33(4): 333–42
Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998; 44(12): 202–8
Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48(4): 624–31
Griffin JW, Li CY, Ho TW, et al. Pathology of the motorsensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39(1): 17–28
Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia, and areflexia). N Engl J Med 1956; 225: 57–75
Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178(5): 1771–5
Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II: antecedent events. J Neurol Neurosurg Psychiatry 1988; 51(5): 613–8
Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case control study. Neurology 1998; 51(4): 1110–5
Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43(10): 1991–7
Jacobs BC, Endtz HP, van der Meche FG, et al. Serum anti-GQ1b antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995; 37: 260–5
Kuroki S, Saida T, Nukina M, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993; 33(3): 243–7
Rees JH, Vaughan RW, Kondeatis E, et al. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995; 62(1): 53–7
Hadden RDM, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56(6): 758–65
Irie S, Saito T, Nakamura K, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996; 68(1–2): 19–26
Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123 (Pt 10): 2171–8
Mori M, Kuwabara S, Miyaké M, et al. Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Neurology 1999; 52(6): 1282–4
Hemachudha T, Griffin DE, Chen WW, et al. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology 1988; 38(3): 375–8
Safranek TJ, Lawrence DN, Kurkland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976–1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991; 133: 952–5
Roscelli JD, Bass JW, Pang R. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980–1988. Am J Epidemiol 1991; 133(9): 952–5
Salisbury DM. Association between oral poliovaccine and Guillain-Barré syndrome? Lancet 1998; 351(9096): 79–80
Wijdicks EFM, Fletcher DD, Lawn ND. Influenzae vaccine and the risk of Guillain-Barré syndrome. Neurology 2000; 55(3): 452–3
Pritchard R, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry 2002; 73: 348–9
Kuwabara S, Ogawara K, Koga M, et al. Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999; 67(2): 180–4
Kuwabara S, Nakata M, Sung JY, et al. Hyperreflexia in axonal Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2002; 199(1–2): 89–92
Ho TW, Lin CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997; 48: 695–700
Kuwabara S, Asahina M, Mori M, et al. Two patterns of clinical recovery in Guillain-Barré syndrome with anti-GMl antibody. Neurology 1998; 51: 1656–60
Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586–90
The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096–2004
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753–61
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow up. Ann Neurol 1992; 32: 94–7
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchange in Guillain-Barré syndrome. Ann Neurol 1997; 41: 298–306
Raphael JC, Chevret S, Hughes RAC. Plasma exchange for Guillain-Barré Syndrome. Cochrane Database of Systematic Review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003
Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma exchange. J Neurol Neurosurg Psychiatry 1991; 54(11): 957–60
Rudnicki S, Vriesendorp F, Koski CL, et al. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 1992; 15(1): 57–62
Imbach P, Barundun S, d’Appuzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; I(8232): 1228–31
van der Meché FGA, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326(17): 1123–9
Plasma Exchanges/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225–30
Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59 (12 Suppl. 6): S13–21
Jacobs BC, van Doom PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40(2): 181–7
Kuwabara S, Mori M, Ogawara K, et al. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001; 24(1): 54–8
Hughes RA, van der Meche FG. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003
Heininger K, Schafer D, Hartung P, et al. The role of macrophages in experimental allergic neuritis induced by P2-specific T-cell line. Ann Neurol 1988; 23: 326–31
Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001; 50: 26–33
Van Koningsveld R, van der Meche FG, Schmitz PI, et al. Combined therapy of intravenous immunoglobulin and methylprednisolone in patients with Guillain-Barré syndrome: the results of a multicentre double blind placebo controlled clinical trial. J Peripher Nerv Syst 2001; 6: 186–7
Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2002; 57(5): 774–80
Schaller B, Radziwill AJ, Steck AJ. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur Neurol 2001; 46(3): 167–8
Miyamoto K, Oka N, Kawasaki T, et al. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 2002; 25(2): 280–2
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuwabara, S. Guillain-Barré Syndrome. CNS Drugs 64, 597–610 (2004). https://doi.org/10.2165/00003495-200464060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200464060-00003